Screener
NeoGenomics NEO Stock-Based Comp
Stock-Based Comp at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by NeoGenomics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: NeoGenomics’s 10-Q, filed July 28, 2026.
- Filed
- Jul 28, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001077183-26-000059
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | ||
| Depreciation | 17,356 | 18,506 |
| Amortization of intangibles | 15,267 | 16,486 |
| Stock-based compensation | 17,852 | 22,968 |
| Non-cash operating lease expense | 3,226 | 3,346 |
| Non-cash finance lease amortization | 322 | 7 |
| Amortization of debt issue costs | 20 | 69 |
| Amortization of convertible debt discount | 753 | 1,164 |
Item 1. Financial Statements (unaudited)
FAQ
- What is NeoGenomics's stock-based comp?
- NeoGenomics (NEO) reported stock-based comp of $8.22M in Q2 2026.
- How has NeoGenomics's stock-based comp changed year-over-year?
- NeoGenomics's stock-based comp decreased by 32.7% year-over-year, from $12.21M to $8.22M.
- What is the long-term trend for NeoGenomics's stock-based comp?
- Over 4 years (2021 to 2025), NeoGenomics's stock-based comp has grown at a 16.5% compound annual growth rate (CAGR), from $22.46M to $41.32M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about NeoGenomics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude